Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobimetinib - Genentech/Exelixis

Next Previous
X
Search
Drug Profile

Cobimetinib - Genentech/Exelixis

Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis; Genentech; InxMed; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Histiocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Registered Histiocytosis
  • Phase III Colorectal cancer
  • Phase II Brain metastases; Breast cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer; Urogenital cancer; Vascular disorders
  • Phase I/II Multiple myeloma; Pancreatic cancer; Solid tumours
  • No development reported Acute myeloid leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uveal melanoma

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Italy (PO)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain (PO)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top